Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 832 · Ensuring Pathways to Innovative Cures Act of 2025 ·

EPIC Act of 2025

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1320f–1 Selection of negotiation-eligible drugs as selected drugs

+2 −01 of 2 shown
More for 42 U.S.C. § 1320f–1
Read § 1320f–1Only this section
2 changes the bill asks for here, 1 carried out
  1. Not carried out:

    by striking year, at least 7 and inserting “year—(I) for initial price applicability years 2026 and 2027, at least 7; and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking QTEXT and inserting “ year — QCONTENT; and
  2. Carried out:

    by adding at the end the following:(II) for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and.

§ 1320f–1(e)(1)In general(A)–(B)

Start of § 1320f–1 to (e)(1)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(A)(i)(i) (i)
that is approved under section 355(c) of title 21 and is marketed pursuant to such approval;that is approved under section 355(c) of title 21 and is marketed pursuant to such approval;
(A)(ii)(ii) (ii)
for which, as of the selected drug publication date with respect to such initial price applicability year, at least 7 years will have elapsed since the date of such approval; andfor which, as of the selected drug publication date with respect to such initial price applicability year, at least 7 years will have elapsed since the date of such approval; and
(A)(ii)(II)(II) [inserted: ]
[inserted: for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and]
(A)(iii)(iii) (iii)
that is not the listed drug for any drug that is approved and marketed under section 355(j) of such title.that is not the listed drug for any drug that is approved and marketed under section 355(j) of such title.
(B)(B) Biological products(B) Biological products
A biological product—A biological product—

Rest of § 1320f–1 unchanged

Step through the changes